skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Successful treatment of solitary toxic thyroid nodules with relatively low-dose iodine-131, with low prevalence of hypothyroidism

Abstract

Forty-five patients with solitary toxic thyroid adenomas received 131I (mean dose, 10.3 mCi) for treatment of hyperthyroidism and were followed for 4.9 +/- 3.2 years (range, 0.5 to 13.5). Seventy-seven percent were euthyroid by 2 months, 91% by 6 months, and 93% by 1 year. Only 3 patients did not respond to a single dose of 131I, but all responded to multiple doses. Late recurrent hyperthyroidism occurred in 3 patients at 4.5, 6, and 10 years after treatment with a single dose of 131I. No patient developed clinical hypothyroidism, and none had a low serum thyroxine level associated with an elevated serum thyrotrophin level. Three patients developed minimal elevations in serum thyrotrophin levels: 1, 4, and 7.5 years after 131I treatment, their thyrotrophin levels were 8.4, 6.2, and 9.6 microU/mL, respectively. All 3 had normal serum thyroxine levels and were clinically euthyroid. Mean serum thyroxine concentrations of all patients were unchanged between 1 and more than 9 years of follow-up. These data suggest that solitary toxic adenomas may be treated with relatively low doses of 131I (5 to 15 mCi), and that post-treatment hypothyroidism is very unusual.

Authors:
; ;
Publication Date:
Research Org.:
Department of Medicine, Massachusetts General Hospital, Boston
OSTI Identifier:
6334474
Resource Type:
Journal Article
Journal Name:
Ann. Intern. Med.; (United States)
Additional Journal Information:
Journal Volume: 101:4
Country of Publication:
United States
Language:
English
Subject:
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.; 62 RADIOLOGY AND NUCLEAR MEDICINE; ADENOMAS; RADIOTHERAPY; SIDE EFFECTS; HYPERTHYROIDISM; IODINE 131; LOW DOSE IRRADIATION; PATIENTS; THYROID; THYROXINE; AMINO ACIDS; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BODY; CARBOXYLIC ACIDS; DAYS LIVING RADIOISOTOPES; DISEASES; ENDOCRINE DISEASES; ENDOCRINE GLANDS; GLANDS; HORMONES; INTERMEDIATE MASS NUCLEI; IODINE ISOTOPES; IRRADIATION; ISOTOPES; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; NUCLEI; ODD-EVEN NUCLEI; ORGANIC ACIDS; ORGANIC COMPOUNDS; ORGANIC HALOGEN COMPOUNDS; ORGANIC IODINE COMPOUNDS; ORGANS; PEPTIDE HORMONES; RADIOISOTOPES; RADIOLOGY; THERAPY; THYROID HORMONES; 560161* - Radionuclide Effects, Kinetics, & Toxicology- Man; 550604 - Medicine- Unsealed Radionuclides in Therapy- (1980-)

Citation Formats

Ross, D.S., Ridgway, E.C., and Daniels, G.H. Successful treatment of solitary toxic thyroid nodules with relatively low-dose iodine-131, with low prevalence of hypothyroidism. United States: N. p., 1984. Web. doi:10.7326/0003-4819-101-4-488.
Ross, D.S., Ridgway, E.C., & Daniels, G.H. Successful treatment of solitary toxic thyroid nodules with relatively low-dose iodine-131, with low prevalence of hypothyroidism. United States. doi:10.7326/0003-4819-101-4-488.
Ross, D.S., Ridgway, E.C., and Daniels, G.H. Mon . "Successful treatment of solitary toxic thyroid nodules with relatively low-dose iodine-131, with low prevalence of hypothyroidism". United States. doi:10.7326/0003-4819-101-4-488.
@article{osti_6334474,
title = {Successful treatment of solitary toxic thyroid nodules with relatively low-dose iodine-131, with low prevalence of hypothyroidism},
author = {Ross, D.S. and Ridgway, E.C. and Daniels, G.H.},
abstractNote = {Forty-five patients with solitary toxic thyroid adenomas received 131I (mean dose, 10.3 mCi) for treatment of hyperthyroidism and were followed for 4.9 +/- 3.2 years (range, 0.5 to 13.5). Seventy-seven percent were euthyroid by 2 months, 91% by 6 months, and 93% by 1 year. Only 3 patients did not respond to a single dose of 131I, but all responded to multiple doses. Late recurrent hyperthyroidism occurred in 3 patients at 4.5, 6, and 10 years after treatment with a single dose of 131I. No patient developed clinical hypothyroidism, and none had a low serum thyroxine level associated with an elevated serum thyrotrophin level. Three patients developed minimal elevations in serum thyrotrophin levels: 1, 4, and 7.5 years after 131I treatment, their thyrotrophin levels were 8.4, 6.2, and 9.6 microU/mL, respectively. All 3 had normal serum thyroxine levels and were clinically euthyroid. Mean serum thyroxine concentrations of all patients were unchanged between 1 and more than 9 years of follow-up. These data suggest that solitary toxic adenomas may be treated with relatively low doses of 131I (5 to 15 mCi), and that post-treatment hypothyroidism is very unusual.},
doi = {10.7326/0003-4819-101-4-488},
journal = {Ann. Intern. Med.; (United States)},
number = ,
volume = 101:4,
place = {United States},
year = {1984},
month = {10}
}